External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐ HIPI ) in the Brazilian Hodgkin lymphoma registry
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19824 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Valeria Buccheri und 23 weiteren Autor:innen. Beteiligte Einrichtung: Instituto do Câncer do Estado de São Paulo/Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Hodgkin Disease, Risk Assessment, Registries. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: US NCI, Division of Hematology, Hemotherapy and Cellular Therapy of Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo (FMUSP), NCI NIH HHS.
Abstract (Originalsprache)
The Hodgkin lymphoma International Study for Individual Care (HoLISTIC) Consortium's A‐HIPI model, developed in 2022 for advanced‐stage classical Hodgkin lymphoma (cHL), predicts survival within 5 years amongst newly diagnosed patients. This study validates its performance in the Brazilian Hodgkin lymphoma registry. By 2022, the Brazilian HL registry included 1357 cHL patients, with a median 5‐year follow‐up. Probabilities for 5‐year progression‐free survival (PFS) and overall survival (OS) were calculated using A‐HIPI‐model equations. Discrimination (Harrell C ‐statistic/Uno C ‐statistic) and calibration measures assessed external validation and calibration. Lab values beyond the allowed range were excluded, mirroring the initial A‐HIPI analysis. A total of 694 advanced‐stage cHL patients met the original inclusion criteria (age 18–65 years, Stage IIB‐IV). Median age was 31 years; 46.3% were females. Stage distribution was IIB (33.1%), III (27.4%), IV (39.5%). Bulky disease in 32.6%. Five‐year PFS and OS were 68.4% and 86.0%, respectively. Harrell C ‐statistics were 0.60 for PFS and 0.69 for OS, and Uno C ‐statistics were 0.63 for PFS and 0.72 for OS. Calibration plots demonstrated well‐calibrated predictions with calibration slopes of 0.91 and 1.03 for 5‐year OS and PFS, respectively. Despite differing patient, clinical characteristics, and socioeconomic factors, the baseline prediction tool performed well in the Brazilian cohort, demonstrating adequate discrimination and calibration. This supports its reliability in diverse settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto do Câncer do Estado de São Paulo/Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Laboratório de Investigação Médica, Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
- Hospital de Cancer de Barretos, Barretos, SP, Brazil.
- Liga Norte Rio Grandense Contra o Câncer, Rio Grande do Norte, Brazil.
- Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, São Paulo, Brazil.
ORCID-Profile: Valeria Buccheri, Irene Biasoli, Fabiola Traina, Cristiana Solza, Leila Perobelli, Rafael Gaiolla, Carla Boquimpani, Kátia Pagnano, Carmino de Souza, Nelson Spector, Angie Mae Rodday, Andrew M Evens, Susan K Parsons
Förderung
- US NCI
- Division of Hematology, Hemotherapy and Cellular Therapy of Hospital das Clinicas - Faculdade de Medicina da Universidade de São Paulo (FMUSP)
- NCI NIH HHS
- CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnologico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Buccheri, V., Moreira, F. R., Biasoli, I., Castro, N., Villarim, C. C., Traina, F., Silveira, T., Praxedes, M. K., Solza, C., Perobelli, L., Baiocchi, O., Gaiolla, R., Boquimpani, C., Sola, C. B., de Paulae Silva, R. O., Ribas, A. C., Pagnano, K., Steffenello, G., de Souza, C., …, & HoLISTIC Consortium (2025). External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐ HIPI ) in the Brazilian Hodgkin lymphoma registry. British Journal of Haematology. https://doi.org/10.1111/bjh.19824
Vancouver
Buccheri V, Moreira FR, Biasoli I, Castro N, Villarim CC, Traina F, et al. External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐ HIPI ) in the Brazilian Hodgkin lymphoma registry. British Journal of Haematology. 2025. doi:10.1111/bjh.19824
BibTeX
@article{Buccheri2025,
author = {Buccheri, Valeria and Moreira, Frederico Rafael and Biasoli, Irene and Castro, Nelson and Villarim, Carolina Colaço and Traina, Fabiola and Silveira, Talita and Praxedes, Monica Kopschitz and Solza, Cristiana and Perobelli, Leila and Baiocchi, Otavio and Gaiolla, Rafael and Boquimpani, Carla and Sola, Caroline Bonamin and de Paulae Silva, Roberta Oliveira and Ribas, Ana Carolina and Pagnano, Kátia and Steffenello, Giovanna and de Souza, Carmino and Spector, Nelson and Rodday, Angie Mae and Evens, Andrew M and Parsons, Susan K and HoLISTIC Consortium, HoLISTIC Consortium},
title = {External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐ HIPI ) in the Brazilian Hodgkin lymphoma registry},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19824}
}
EUVIMED